NASDAQ:ALDX

Aldeyra Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy ALDX

*Your capital is at risk

$2.05

+0.0900 (+4.59%)

At Close: Jun 22, 2026

Aldeyra Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -29.07. In total, the insiders bought 5.15M and sold 6.9M ALDX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-29.07
● Buy	5.15M shares
● Sell	6.9M shares
92% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Jun 03, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -29.07. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (92% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Phillips Gary M. Director	Director	4 977 Value: $9K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Phillips Gary M. Director	Director	6 636 Value: $11.4K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Douglas Richard Director	Director	19 909 Value: $34.2K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Douglas Richard Director	Director	70 000 Value: $120.4K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Miller-rich Nancy Director	Director	70 000 Value: $120.4K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Miller-rich Nancy Director	Director	3 318 Value: $6K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Douglas Richard Director	Director	2 323 Value: $4K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Phillips Gary M. Director	Director	70 000 Value: $120.4K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Clark William D Director	Director	70 000 Value: $120.4K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Clark William D Director	Director	2 323 Value: $4K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Walker Neal Director	Director	70 000 Value: $120.4K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Walker Neal Director	Director	3 318 Value: $6K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Bronstein Ben Director	Director	70 000 Value: $120.4K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Bronstein Ben Director	Director	5 309 Value: $9K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Bronstein Ben Director	Director	4 977 Value: $9K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Deptula-hicks Darlene M Director	Director	84 557 Value: $145.4K
Jun 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Deptula-hicks Darlene M Director	Director	9 756 Value: $16.8K
Jun 09, 2026 Buy	Common Stock J-Other	Deptula-hicks Darlene M Insider	Other	0 Value: $0
Jun 03, 2026 Buy	Common Stock P-Purchase	Brady Todd C President And CEO	CEO / President	250 000 Value: $418.5K
Mar 27, 2026 Buy	Bonus Units A-Award	Brady Todd C President And CEO	CEO / President	632 318 Value: $1.12M
Mar 27, 2026 Buy	Stock Option (right to buy) A-Award	Brady Todd C President And CEO	CEO / President	1 880 510 Value: $3.33M
Mar 19, 2026 Buy	Common Stock P-Purchase	Douglas Richard Director	Director	70 000 Value: $98.0K
Mar 18, 2026 Buy	Common Stock P-Purchase	Alfieri Michael Principal Financial Officer	Officer	5 000 Value: $7K
Aug 13, 2025 Buy	Common Stock P-Purchase	Alfieri Michael Principal Financial Officer	Officer	2 500 Value: $13.3K
Aug 13, 2025 Buy	Common Stock P-Purchase	Alfieri Michael Principal Financial Officer	Officer	2 500 Value: $13.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ALDEYRA THERAPEUTICS

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical tria...

Read Full Profile Here